Table 1. Baseline and treatment characteristics of patients undergoing fractionated CyberKnife radiosurgery for PAs.
| Characteristics | n (%) |
|---|---|
| Total cases | 278 |
| Sex | |
| Male | 167 (60.1) |
| Female | 111 (39.9) |
| Mean age (years) | 40.13 ±12.61 |
| Median follow-up in months (IQR) | 12(20) |
| Previous surgery | 234 (84.8) |
| Deaths in the follow-up period among the total cohort | 5(1.8%) |
| Type of adenoma | |
| Non-functional | 169 (60.8) |
| Functional | 109 (39.2) |
| GH-secreting | 89 (32) |
| ACTH-secreting | 17 (6.1) |
| Medically refractory prolactinoma | 03 (1.1) |
| Pre-CK SRS visual deficit | |
| Partially affected | 239 (90.2) |
| No vision | 05 (1.9) |
| Normal vision | 21 (7.9) |
| Missing data from the total cohort | 13(4.7%) |
| Pre CK SRS hypopituitarism | 87 (32.0) |
| New onset hypopituitarism | |
| NFA | 17 (12.3) |
| FA | 09 (10.3) |
| Post-CK SRS toxicity | 6 (2.6) |
| Radiosurgery prescribed dose (Gy) | |
| Mean | 25.0 |
| IQR | 5.0 |
| Fractions | 5 or 3 |
| GTV (mm) | |
| Median | 7,143.5 |
| IQR | 5,937 |
| CI | |
| Median | 1.31 |
| IQR | 0.13 |
| nCI | |
| Median | 1.35 |
| IQR | 0.14 |
| HI | |
| Median | 1.25 |
| IQR | 0.04 |
| Coverage | |
| Median | 97.02 |
| IQR | 3.62 |
IQR: Inter-quartile range; GH: Growth hormone; ACTH: Adrenocorticotrophic hormone; CK SRS: CyberKnife stereotactic radiosurgery; NFA: Nonfunctional adenoma; FA: Functional adenoma; Gy: Gray; GTV: Gross tumour volume; CI: Conformity index; nCI: New conformity index; HI: Homogeneity index